The use of clopidogrel and aprotonin in off pump coronary artery bypass grafting

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-002652-42-GB

Enrollment

270

Registered

2007-06-26

Start date

2007-08-14

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding after coronary artery bypass grafting MedDRA version: 9.1 Level: LLT Classification code 10005645 Term: Blood loss of (NOS)

Interventions

Trade Name: Plavix Product Name: clopidogrel Pharmaceutical Form: Tablet CAS Number: 94188848 Other descriptive name: CLOPIDOGREL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Informed consent Scheduled for OPCAB surgery Currently taking clopidogrel 75mg/day Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Emergency procedures Pre existing coagulation abnormalities Warfarin therapy

Design outcomes

Primary

Measure	Time frame
Main Objective: • To investigate whether clopidogrel administration peri operatively affects peri operative blood loss in off pump cardiac surgery. ; Secondary Objective: • To investigate if aprotonin administration to patients receiving clopidogrel in off pump cardiac surgery reduces peri operative blood loss. • To determine if the degree of platelet inhibition as demonstrated by the modified thromboelastography (TEG) correlates with blood loss in off pump cardiac surgery. ; Primary end point(s): Blood loss (intraoperatively into suction and post operative chest drain losses)	—

Measure

Time frame

Main Objective: • To investigate whether clopidogrel administration peri operatively affects peri operative blood loss in off pump cardiac surgery. ; Secondary Objective: • To investigate if aprotonin administration to patients receiving clopidogrel in off pump cardiac surgery reduces peri operative blood loss. • To determine if the degree of platelet inhibition as demonstrated by the modified thromboelastography (TEG) correlates with blood loss in off pump cardiac surgery. ; Primary end point(s): Blood loss (intraoperatively into suction and post operative chest drain losses)

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026